Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (2738)	11/27/1998 8:04:00 PM
From: Maurice Winn	Read Replies (1) \| Respond to of 3702

biz.yahoo.com More on Neurocrine. SAN DIEGO Nov 25 Results of a Phase I study with IL-4 Fusion Toxin (NBI-3001) were presented last week at The Society for Neuro-Oncology Meeting in San Francisco. It was infused into brain tumors and surrounding parenchyma via convection catheter delivery in nine patients with recurrent malignant gliomas. This produced no evident systemic or neurological toxicities. Of nine patients treated, five showed necrosis in major sections of tumor. The phase I study was conducted by Dr Robert Rand at the John Wayne Cancer Institute in collaboration with the inventors Dr Raj Puri from the Center for Biologics Evaluation and Research of the Food and Drug Administration and Dr Ira Pastan of the Laboratory of Molecular Biology, National Institutes of Health. Neurocrine licensed exclusive worldwide rights to NBI-3001 from the NIH in May 1998. ------------------------------------------------------------ Speak of the devil [FDA]! See, confirmation that some people in the FDA are doing a great job. Maybe an infusion of TNT after this NBI-3001 would leave tumors really in trouble. TNT hooking onto all the necrotic tissue left after the NBI-3001 has done it's job sounds a good scheme. Maurice